Top

Published in:

01-06-2016

Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer

Authors: James L. Klosky, Brianne Favaro, Kelly R. Peck, Jessica L. Simmons, Kathryn M. Russell, Daniel M. Green, Melissa M. Hudson

Published in: Journal of Cancer Survivorship | Issue 3/2016

Abstract

Purpose

Human papillomavirus (HPV) is a sexually transmitted infection and the cause of cervical and other cancers. Vaccination is available to protect against genital HPV and is recommended for individuals aged 9–26 years. This study aimed to estimate the prevalence of HPV vaccination among childhood cancer survivors and to identify factors associated with vaccine outcomes.

Methods

Young adult females with (n = 114; M age = 21.18 years, SD = 2.48) and without (n = 98; M age = 20.65 years, SD = 2.29) a childhood cancer history completed surveys querying HPV vaccination initiation/completion, as well as sociodemographic, medical, and health belief factors. Multivariable logistic regression was used to calculate odds ratios (ORs) and 95 % confidence intervals (CIs) for vaccine outcomes.

Results

Among survivors, 38.6 % (44/114) and 26.3 % (30/114) initiated or completed vaccination compared to 44.9 % (44/98) and 28.6 % (28/98) among controls, respectively. In the combined survivor/control group, physician recommendation (OR = 11.24, 95 % CI 3.15–40.14) and familial HPV communication (OR = 7.28, 95 % CI 1.89–28.05) associated with vaccine initiation. Perceptions of vaccine benefit associated with vaccine completion (OR = 10.55, 95 % CI 1.59–69.92), whereas perceptions of HPV-related severity associated with non-completion (OR = 0.14, 95 % CI 0.03–0.71).

Conclusion

Despite their increased risk for HPV-related complication, a minority of childhood cancer survivors have initiated or completed HPV vaccination. Modifiable factors associated with vaccine outcomes were identified.

Implications for Cancer Survivors

HPV vaccination is a useful tool for cancer prevention in survivorship, and interventions to increase vaccine uptake are warranted.

Satterwhite CL, Torrone E, Meites E, Dunne EF, Majahan R, Ocfemia MC, et al. Sexually transmitted infections among U.S. women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187–93.CrossRefPubMed

American Cancer Society. Supplement: assessing the burden of HPV-associated cancers in the United States. Cancer. 2008;113(S10):2837–3057.CrossRef

Steinau M, Unger ER, Hernandez BY, Goodman MT, Copeland G, Hopenhayn C, et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis. 2013;17:397–403.CrossRefPubMedPubMedCentral

Gargano JW, Wilkinson EJ, Unger ER, Steinau M, Watson M, Huang Y, et al. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis. 2012;16:471–9.CrossRefPubMed

Schiller JT, Frazer IH, Lowry DR. Human papillomavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. China: Saunders; 2008. p. 243–57.

Hopfer S, Clippard JR. College women’s HPV vaccine decision narratives. Qual Health Res. 2010;10:1–16.

Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158–71.CrossRefPubMed

Haydon AA, Herring AH, Prinstein MJ, Helpern CT. Beyond age at first sex: patterns of emerging sexual behavior in adolescence and young adulthood. J Adolesc Health. 2013;50:456–63.CrossRef

Centers for Disease Control and Prevention. Genital HPV infection: CDC fact sheet, 2015. Available from http://www.cdc.gov/std/HPV/STDFact-HPV.htm

10.

Ojha RP, Tota JE, Offutt-Powerll TN, Klosky JL, Ashokkumar R, Gurney JG. Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers. PLoS ONE. 2013;8:e70349.CrossRefPubMedPubMedCentral

11.

Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7–28.CrossRefPubMed

12.

Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years—United States, 2012. MMWR Morb Mortal Wkly Rep. 2012;61:1–4.

13.

Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, 2008. Available from http://www.survivorshipguidelines.org/

14.

Laz TH, Rahman M, Berenson AB. Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010. Cancer. 2012;119:1386–92.CrossRefPubMedPubMedCentral

15.

Schmidt S, Parsons HM. Vaccination interest and trends in human papillomavirus vaccine uptake in young adult women aged 18 to 26 years in the United States: an analysis using the 2008–2012 National Health Interview Survey. Am J Public Health. 2014;104:946–53.CrossRefPubMedPubMedCentral

16.

Hopfer S, Clippard JR. College women’s HPV vaccine decision narratives. Qual Health Res. 2011;21:262–77.CrossRefPubMed

17.

Pierre Joseph N, Clark JA, Mercilus G, Wilbur M, Figaro J, Perkins R. Racial and ethnic differences in HPV knowledge, attitudes, and vaccination rates among low-income African-American, Haitian, Latina, and Caucasian young adult women. J Pediatr Adolesc Gynecol. 2014;27:83–92.CrossRefPubMed

18.

Bednarczyk RA, Birkhead GS, Morse DL, Doleyres H, McNutt LA. Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at New York State University, 2010. Vaccine. 2011;29:3138–43.CrossRefPubMed

19.

Manhart LE, Burgess-Hull AJ, Fleming CB, Bailey JA, Haggerty KP, Catalano RF. HPV vaccination among a community sample of young adult women. Vaccine. 2011;29:5238–44.CrossRefPubMedPubMedCentral

20.

Donadiki EM, Jimenez-Garcia R, Hernandez-Barrera V, Carrasco-Garrido P, Lopez de Andres A, Velonakis EG. Human papillomavirus vaccination coverage among Greek higher education female students and predictors of vaccine uptake. Vaccine. 2012;30:6967–70.CrossRefPubMed

21.

Roberts ME, Gerrard M, Reimer R, Gibbons FX. Mother-daughter communication and human papillomavirus vaccine uptake by college students. Pediatrics. 2010;125:982–9.CrossRefPubMed

22.

Daley MF, Crane LA, Markowitz LE, Black SR, Beaty BL, Barrow J, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics. 2010;126:425–33.CrossRefPubMed

23.

Rosenthal SL, Rupp R, Zimet GD, Meza HM, Loza ML, Short MB, et al. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. J Adolesc Health. 2008;43:239–45.CrossRefPubMed

24.

Ojha RP, Jackson BE, Tota JE, Offutt-Powell TN, Hudson MM, Gurney JG. Younger age distribution of cervical cancer incidence among survivors of pediatric and young adult cancers. Gynecol Oncol. 2014;134:309–13.CrossRefPubMed

25.

Klosky JL, Russell KM, Canavera KE, Gammel HL, Hodges JR, Foster RH, et al. Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer. Cancer Prev Res. 2013;6:1101–10.CrossRef

26.

Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine. 2006;24:3087–94.CrossRefPubMed

27.

Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40:108–15.CrossRefPubMed

28.

Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486–93.CrossRefPubMed

29.

Kelly JA, McAuliffe TL, Sikkema KJ, Murphy DA, Somlai AM, Mulry GW, et al. Reduction in risk behavior among adults with severe mental illness who learned to advocate for HIV prevention. Psychiatr Serv. 1997;48:1283–8.CrossRefPubMed

30.

Kelly JA, Murphy DA, Bahr GR, Brasfield TL, Davis DR, Hauth AC, et al. AIDS/HIV risk behavior among the chronic mentally ill. Am J Psychiatry. 1992;149:886–9.CrossRefPubMed

31.

Gomez CA, Marin BV. Gender, culture, and power: barriers to HIV-prevention strategies for women. J Sex Res. 1996;33:355–62.CrossRef

32.

Cox DS, Cox AD, Sturm L, Zimet G. Behavioral interventions to increase HPV vaccination acceptability among mothers of young girls. Health Psychol. 2010;29:29–39.CrossRefPubMed

33.

Gerend MA, Lee SC, Shepherd JE. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis. 2007;34:468–71.PubMed

34.

Mariotto AB, Rowland JH, Yarbroff KR, Scoppa S, Hachey M, Ries L, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:1033–40.CrossRefPubMed

35.

Krull KR, Huang S, Gurney JG, Klosky JL, Leisenring W, Termuhlen A, et al. Adolescent behavior and adult health status in childhood cancer survivors. J Cancer Surviv. 2010;4:210–7.CrossRefPubMedPubMedCentral

36.

Rahman M, Laz TH, Berenson AB. Geographic variation in human papillomavirus vaccination uptake among young adult women in the United States during 2008–2010. Vaccine. 2013;31:5495–9.CrossRefPubMedPubMedCentral

37.

Klosky JL, Gamble HL, Spunt SL, Randolph ME, Green DM, Hudson MM. Human papillomavirus (HPV) vaccine in survivors of childhood cancer. Cancer. 2009;115:5627–36.CrossRefPubMedPubMedCentral

38.

Ojha RP, Tota JE, Offutt-Powell TN, Klosky JL, Ashokkumar R, Gurney JG. The accuracy of human papillomavirus vaccination status based on adult proxy recall or household immunization records for adolescent females in the United States: results from the National Immunization Survey-Teen. Ann Epidemiol. 2013;23:281–5.CrossRefPubMed

39.

Rolnick SJ, Parker ED, Nordin JD, Hedblom BD, Wei F, Kerby T, et al. Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors? Vaccine. 2013;31:3928–35.CrossRefPubMedPubMedCentral

40.

Arora NK, Jensen RE, Sulayman N, Hamilton AS, Potosky AL. Patient-physician communication about health-related quality-of-life problems: are non-Hodgkin lymphoma survivors willing to talk? J Clin Oncol. 2013;31:3964–70.CrossRefPubMedPubMedCentral

41.

Askelson NM, Campo S, Smith S, Lowe JB, Dennis L, Andsager J. Assessing physicians’ intention to talk about sex when they vaccinate nine-year-old to 15-year-old girls against HPV. Sex Educ. 2011;11:431–41.CrossRef

42.

McRee AL, Reiter PL, Gottlieb SL, Brewer NT. Mother-daughter communication about HPV vaccine. J Adolesc Health. 2011;48:314–7.CrossRefPubMedPubMedCentral

43.

Murphy D, Klosky JL, Reed D, Termuhlen A, Shannon SV, Quinn GP. The importance of assessing priorities of reproductive health concerns among adolescent and young adult (AYA) patients with cancer. Cancer. 2015;121:2529–36.CrossRefPubMed

Title: Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer
Authors: James L. Klosky
Brianne Favaro
Kelly R. Peck
Jessica L. Simmons
Kathryn M. Russell
Daniel M. Green
Melissa M. Hudson
Publication date: 01-06-2016
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 3/2016
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-015-0495-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 3/2016

The Cognitive Symptom Checklist-Work in cancer patients is related with work functioning, fatigue and depressive symptoms: a validation study

The provision of workplace accommodations following cancer: survivor, provider, and employer perspectives

The salience of cancer and the “survivor” identity for people who have completed acute cancer treatment: a qualitative study

Improving an electronic system for measuring PROs in routine oncology practice

Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors

Patterns and predictors of survivorship clinic attendance in a population-based sample of pediatric and young adult childhood cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer